muramidase and Remission--Spontaneous

Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Bone Marrow Cells; Cerebral Hemorrhage; Daunorubicin; Female; Gastrointestinal Hemorrhage; Glucuronidase; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Monocytes; Muramidase; Naphthol AS D Esterase; Periodic Acid-Schiff Reaction; Peroxidases; Pregnancy; Prognosis; Remission, Spontaneous

Topics: Acute Disease; Aged; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Muramidase; Remission, Spontaneous

Mitotic indices, labeling indices (LI), and tritiated thymidine incorporation into DNA of marrow cells were conducted in patients with leukemia to determine if correlations existed between kinetic measurements, clinical features, and response to chemotherapy. Higher proliferative activity was observed in chronic granulocytic leukemia (CGL) and blastic phase of CGL than in acute leukemia. In acute myelogenous leukemia there was no correlation with various clinical features studied. Those patients demonstrating greater than 60% reduction in circulating leukemia cells within 7 days had a higher initial LI than those with less than 60% reduction. Cytosine arabinoside, methotrexate, and hydroxyurea were investigated to determine their synchronizing capability; cytosine arabinoside and methotrexate were superior to hydroxyurea. In a cycle-sensitive schedule specifically designed to synchronize cells, responses occurred more frequently in patients who increased thier LI 48 hours after priming doses of cytosine arabinoside. In an intensive-chemotherapy schedule which produced more remissions than the cycle-sensitive schedule, there was no relationship between initial kinetic measurements and response. Kinetic values increased as patients achieved remissions.

Topics: Adult; Antineoplastic Agents; Bone Marrow; Cell Division; DNA; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Kinetics; Leukemia; Male; Middle Aged; Mitotic Index; Muramidase; Remission, Spontaneous; Time Factors

A 30-year-old Japanese woman relapsed into sarcoidosis after two successive parturitions. The cutaneous lesions consisted of scar sarcoidosis, papular type, nodular type, and subcutaneous nodules with histologically typical "naked tubercles". Hypergammaglobulinemia, elevation of both serum angiotensin converting enzyme and lysozyme levels, and bilateral hilar lymphadenopathy were found in the acute and subacute stages, and spontaneously returned to normal levels 16 months after the onset. Our case suggests that parturition may trigger the onset of sarcoidosis.

Topics: Acute Disease; Adult; Female; Humans; Hypergammaglobulinemia; Labor, Obstetric; Muramidase; Peptidyl-Dipeptidase A; Pregnancy; Pregnancy Complications; Recurrence; Remission, Spontaneous; Sarcoidosis; Skin Diseases

Seventy-four cases of pure acute monoblastic leukemia (AMol) have been retrospectively studied. All patients were treated at Hospital Saint-Louis between 1970 and 1978. Diagnosis was based on morphological and cytochemical features according to the FAB classification. This type of leukemia occurred at any age and in both sexes, with a high frequency of extramedullary involvements. Hyperleukocytosis was very frequent and was significantly correlated with increased blood and urine levels of lysozyme, with renal failure and hypokalemia, and with coagulation abnormalities. AMol still has a poor prognosis, despite a best remission rate (75%) obtained with rubidazone, since the duration of complete remission was short. Central nervous irradiation prolonged remission and prevented meningeal relapses, while 6 meningeal relapses occurred in the patients not irradiated. The high frequency of the extramedullary relapses, including gum and skin, emphasized the question of persistant blast cell sanctuaries after achievement of bone marrow remissions. A more intensive induction with several drugs active against monoblasts could be more efficient and prolong the duration of complete remissions.

Topics: Adolescent; Adult; Aged; Aging; Blood Urea Nitrogen; Child; Child, Preschool; Creatinine; Disseminated Intravascular Coagulation; Female; Hemostasis; Humans; Infant; Leukemia, Monocytic, Acute; Male; Middle Aged; Muramidase; Remission, Spontaneous; Retrospective Studies

Serum lysozyme activity was measured in samples from adult patients with acute leukemia, malignant tumors, and in normal adults. Twenty-eight adult patients with acute myelogenous leukemia (AML) had significantly elevated levels of lysozyme at diagnosis, and none of the adults fell within the normal range. Thirty-two patients with AML in complete remission had lysozyme levels comparable to normal adults, whereas patients with AML in relapse (eight cases) also had abnormally high levels of lysozyme activity. Ten patients with AML in remission and off therapy also had normal lysozyme levels. Three patients with acute lymphatic leukemia had normal lysozyme levels, while one child with monomyelocytic leukemia had substantially elevated lysozyme levels before treatment. It seems that in patients in remission and with normal blood values, the serum lysozyme activity is valuable for monitoring the remission.

Topics: Adult; Antineoplastic Agents; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Muramidase; Prognosis; Remission, Spontaneous

Serum lysozyme activity was measured in samples from children with acute leukemia, malignant tumours, and in normal children. All children with acute lymphatic leukemia (ALL) had significantly reduced levels of lysozyme at diagnosis, and none of the children fell within the normal range. Children with ALL in complete remission had lysozyme levels comparable to normal chidren, while children with ALL in relapse also had pathological low levels. Children with ALL in remission and off therapy also had normal levels of lysozyme. Children with acute myelogenous leukemia had normal lysozyme levels, while children with monomyelocytic leukemia had substantially elevated lysozyme levels before treatment. Determination of serum lysozyme activity in children with acute leukemia is of value both for diagnosis and for evaluating the effect of therapy.

Topics: Acute Disease; Child; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Muramidase; Remission, Spontaneous

Pre-treatment sera from 88 adult patients with acute myelogenous leukaemia have been assayed for their lysozyme content. All 19 patients who presented with a serum-lysozyme level below 15 mug/ml failed to acheive haematological remission from intensive chemotherapy. Serum-lysozyme levels above 85 mug/ml were found in 10 patients, all of whom went into remission. Remissions in this group were, however, shortlived. Of the 59 patients with lysozyme levels between 15 and 85 mug/ml, 39 achieved haematological remission and 12 survived longer than 60 weeks. These findings suggest that estimation of serum-lysozyme may help to identify those patients who are unlikely to respond to the intensive-chemotherapy protocols currently advocated and who could therefore be spared exposure to them.

Topics: Adult; Antineoplastic Agents; Humans; Leukemia, Myeloid, Acute; Muramidase; Prognosis; Remission, Spontaneous

Topics: Humans; Leukemia, Myeloid, Acute; Muramidase; Prognosis; Remission, Spontaneous

Nineteen children aged from 3 to 16 years with first long-term hematologic remission were studied. Cell-mediated immunity was assayed by the reaction to dinitrochlorobenzene (DNCB), nitroblue tetrazolium reduction test (NBT) and lysozyme activity. Humoral immunity was determined by immunoglobulin (IgG, IgA, IgM) levels in serum. The DNCB-reaction was positive in 50% of children treated from 12 to 36 months. Percentage and absolute counts of NBT-positive granulocytes and lysozyme/granulocyte ratio systematically increased with time of therapy. In all studied children IgG was normal, IgA and IgM were depressed to 40% and 76% of normal value (with the exception of 2 children after cessation of therapy, in which IgA was normal). It seemed that continuous control of the immunologic status during long-term cytostatic therapy is essential in clinical practice.

Topics: Adolescent; Adult; Child; Child, Preschool; Dinitrochlorobenzene; Humans; Hypersensitivity; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Leukemia, Lymphoid; Muramidase; Nitroblue Tetrazolium; Remission, Spontaneous

In the present experimental study the role of lysozyme drops in healing of corneal ulcer of staphylococcal origin (sensitive to chloramphenicol) was studied on 16 albino rabbits. In 8 rabbits, in one eye placibo drops (distilled water) and in the other eye lysozyme 1% were put 4 times daily. In the other 8 rabbits, in one eye chloramphenicol drops 0.4% and in the other eye chloramphenicol drops 0.4% + lysozyme drops 1% were instilled 4 times daily. It was observed that the rate of healing of corneal ulcer was much earlier in the eyes which had local instillation of chloramphenicol drops + lysozyme in comparison to the eyes which had only chloramphenicol drops, lysozyme drops, or distilled water.

Topics: Animals; Chloramphenicol; Corneal Ulcer; Muramidase; Ophthalmic Solutions; Rabbits; Remission, Spontaneous

Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Anemia; Child; Cytarabine; DNA, Neoplasm; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Muramidase; Nausea; Remission, Spontaneous; Sex Factors; Thioguanine; Thrombocytopenia; Time Factors; Vomiting

Topics: Adult; Female; Hematologic Diseases; Humans; L-Lactate Dehydrogenase; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Activation; Male; Muramidase; Remission, Spontaneous; Uric Acid

Topics: Adult; Cytarabine; Daunorubicin; Diagnosis, Differential; Drug Evaluation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Muramidase; Prognosis; Remission, Spontaneous; Thymidine; Tritium

Topics: Acute Disease; Antineoplastic Agents; Blood Bactericidal Activity; Complement System Proteins; Escherichia coli; Female; Humans; Immunoglobulins; Leukemia, Myeloid; Male; Muramidase; Remission, Spontaneous; Transferrin

Topics: Adult; Bone Marrow; Bone Marrow Cells; Female; Hematopoiesis; Humans; Leukemia; Leukocyte Count; Male; Middle Aged; Muramidase; Remission, Spontaneous

Topics: Adrenal Cortex Hormones; Clinical Enzyme Tests; Female; Humans; Male; Muramidase; Remission, Spontaneous; Sarcoidosis; Spleen; Splenic Diseases

Topics: Acute Disease; Adenine Nucleotides; Adenosine Diphosphate; Adult; Aged; Blood Platelets; Collagen; Epinephrine; Female; Fibrin; Humans; Kaolin; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Muramidase; Platelet Adhesiveness; Remission, Spontaneous; Thrombin

Topics: Adult; Aged; Blood Cell Count; Bone Marrow Cells; Bone Marrow Examination; Child; Cytarabine; Densitometry; Female; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Muramidase; Remission, Spontaneous; Thioguanine; Vincristine

A regimen of intravenous cyclophosphamide, cytarabine and vincristine, given over a four-day period and repeated every two to three weeks, was used to treat 33 patients with acute myeloblastic leukemia. Of the 30 evaluable patients 9/18 previously untreated patients achieved complete remission and two others marked improvement, and 4/12 previously treated patients achieved complete remission. Twelve of 16 patients under the median age of 38 responded while only 3/14 patients over this age responded. There was no difference in response between those with elevated muramidase levels and those with normal levels. Three patients developed a previously unrecognized syndorme of fever, malaise, rash and orbital suffusion. Cytarabine was probably responsible.At least four courses of treatment are required before abandoning this regimen of therapy. Patients who achieve a complete remission and live for more than 150 days spend about 25% of their total survival time from diagnosis in hospital.

Topics: Adult; Age Factors; Cyclophosphamide; Cytarabine; Evaluation Studies as Topic; Female; Hepatitis; Hepatitis B Antigens; Hospitalization; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Muramidase; Remission, Spontaneous; Vincristine

Topics: Administration, Oral; Adult; Drug Evaluation; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Muramidase; Recurrence; Remission, Spontaneous; Stomatitis, Aphthous; Tablets

Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Bone Marrow Examination; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Leukocytes; Male; Muramidase; Nitrophenols; Remission, Spontaneous; Sarcoidosis

Topics: Adult; Antibodies; Female; Humans; Male; Middle Aged; Muramidase; Psoriasis; Remission, Spontaneous

Topics: Adult; Densitometry; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Muramidase; Remission, Spontaneous